• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性直肠癌诱导系统治疗后的完全微创分步切除术。

Total Minimally Invasive Curative Staged Resections After Induction Systemic Therapy for Metastatic Rectal Cancer.

机构信息

Department of General Surgery, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan.

Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan.

出版信息

Cancer Rep (Hoboken). 2024 Nov;7(11):e70051. doi: 10.1002/cnr2.70051.

DOI:10.1002/cnr2.70051
PMID:39506835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11541059/
Abstract

BACKGROUND

Intensified systemic chemotherapy following minimally invasive surgery for patients with unresectable metastatic colorectal cancer is performed to achieve curative resection and improve quality of life. We report a case of initially unresectable rectal cancer with metastases treated with laparoscopic and thoracoscopic staged resections after triplet chemotherapy plus bevacizumab.

CASE

A 71-year-old man was referred to our hospital to examine the cause of constipation. A circumferential adenocarcinoma with extramural invasion and lateral lymphadenopathy was identified in the lower rectum with simultaneous metastatic liver and lung tumors. Intensified triplet chemotherapy plus bevacizumab was conducted to treat oncologically unresectable rectal cancer to avoid positive radial margins during surgical resection. Eleven cycles of chemotherapy resulted in regression of the tumors with metastases. Laparoscopic low anterior resection with lateral lymph node dissection was performed. Three months later, laparoscopic liver resection of the posterosuperior segment was performed without complications. Finally, the patient underwent thoracoscopic-assisted pulmonary segmentectomy of the right basal lobe. All resected tumors had negative surgical margins, and the patient has been surviving without adjuvant chemotherapy.

CONCLUSION

Minimally invasive staged resection and intensified chemotherapy for the treatment of initially unresectable metastatic colorectal cancer should be performed by a skilled surgical team in coordination with a multidisciplinary team.

摘要

背景

对于不可切除的转移性结直肠癌患者,在微创手术后进行强化全身化疗,旨在实现根治性切除并改善生活质量。我们报告了一例初始不可切除的直肠腺癌伴转移患者,在三联化疗加贝伐珠单抗治疗后,行腹腔镜和胸腔镜分期切除术。

病例

一名 71 岁男性因便秘就诊。直肠下段见环形腺癌伴外侵和侧方淋巴结转移,同时伴有肝和肺转移瘤。为避免手术切除时出现阳性切缘,对不能进行手术切除的直肠腺癌进行了强化三联化疗加贝伐珠单抗治疗。11 个周期的化疗使肿瘤伴转移灶缩小。行腹腔镜低位前切除术加侧方淋巴结清扫术。3 个月后,行腹腔镜肝后上段切除术,无并发症发生。最后,行胸腔镜辅助右基底段肺段切除术。所有切除的肿瘤均无手术切缘阳性,患者未行辅助化疗,目前仍存活。

结论

对于初始不可切除的转移性结直肠癌,应由熟练的外科团队与多学科团队合作,进行微创分期切除术和强化化疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/6cddf0767fe9/CNR2-7-e70051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/f4e3b1bc2b14/CNR2-7-e70051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/5a5e75b65f12/CNR2-7-e70051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/2c6efe801cc7/CNR2-7-e70051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/d4113d978a24/CNR2-7-e70051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/f666a11421c0/CNR2-7-e70051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/bb4b3e8f52e1/CNR2-7-e70051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/14a07e7517c0/CNR2-7-e70051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/6cddf0767fe9/CNR2-7-e70051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/f4e3b1bc2b14/CNR2-7-e70051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/5a5e75b65f12/CNR2-7-e70051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/2c6efe801cc7/CNR2-7-e70051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/d4113d978a24/CNR2-7-e70051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/f666a11421c0/CNR2-7-e70051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/bb4b3e8f52e1/CNR2-7-e70051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/14a07e7517c0/CNR2-7-e70051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5766/11541059/6cddf0767fe9/CNR2-7-e70051-g005.jpg

相似文献

1
Total Minimally Invasive Curative Staged Resections After Induction Systemic Therapy for Metastatic Rectal Cancer.转移性直肠癌诱导系统治疗后的完全微创分步切除术。
Cancer Rep (Hoboken). 2024 Nov;7(11):e70051. doi: 10.1002/cnr2.70051.
2
Segment 7 Laparoscopic Liver Resection: Is It Possible to Resect When Metastatic Lesions Border Suprahepatic Veins?第七部分 腹腔镜肝切除术:当转移病灶位于肝上静脉边界时是否可行切除?
J Gastrointest Surg. 2018 Sep;22(9):1643-1644. doi: 10.1007/s11605-018-3824-8. Epub 2018 May 31.
3
Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?IV 期直肠癌伴肝转移:原发肿瘤切除有获益吗?
World J Surg. 2010 May;34(5):1102-8. doi: 10.1007/s00268-010-0483-7.
4
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.IV期直肠癌单纯术前化疗后的完全病理缓解(ypT0N0M0)
BMC Surg. 2014 Jan 17;14:4. doi: 10.1186/1471-2482-14-4.
5
Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer.成功切除直肠癌异时性主动脉旁、魏尔啸淋巴结及肝转移复发灶。
World J Gastroenterol. 2015 Nov 28;21(44):12722-8. doi: 10.3748/wjg.v21.i44.12722.
6
[Mixed adenoneuroendocrine carcinoma with multiple liver metastases successfully treated by cetuximab/CPT-11 chemotherapy followed by curative resection - a case report].[西妥昔单抗/伊立替康化疗后行根治性切除成功治疗伴有多发肝转移的混合性腺神经内分泌癌——1例报告]
Gan To Kagaku Ryoho. 2014 Nov;41(12):2145-7.
7
Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.根治性肝切除联合5-氟尿嘧啶/亚叶酸钙、奥沙利铂及贝伐单抗治疗升结肠癌伴肺和43处肝转移:病例报告
Int Surg. 2012 Jan-Mar;97(1):6-13. doi: 10.9738/CC88.1.
8
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.FOLFOXIRI 联合贝伐珠单抗作为初始不可切除转移性结直肠癌患者的转化治疗:系统评价和汇总分析。
JAMA Oncol. 2017 Jul 13;3(7):e170278. doi: 10.1001/jamaoncol.2017.0278.
9
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.贝伐珠单抗联合 mFOLFOX-6 或 FOLFOXIRI 方案治疗初治不可切除的结直肠癌肝转移患者:OLIVIA 多中心随机 II 期临床试验。
Ann Oncol. 2015 Apr;26(4):702-708. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.
10
[Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].两例接受FOLFOXIRI联合贝伐单抗化疗的转移性直肠癌患者
Gan To Kagaku Ryoho. 2016 Nov;43(12):1705-1707.

本文引用的文献

1
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.初治不可切除的结直肠癌肝转移患者的一线全身治疗策略(CAIRO5):一项来自荷兰结直肠癌研究组的开放标签、多中心、随机、对照3期研究
Lancet Oncol. 2023 Jul;24(7):757-771. doi: 10.1016/S1470-2045(23)00219-X. Epub 2023 Jun 14.
2
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.转移性结直肠癌的治疗:ASCO 指南。
J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Laparoscopic staged colon-first resection for metastatic colorectal cancer: Perioperative and midterm outcomes from a single-center experience.腹腔镜分期结肠优先切除术治疗转移性结直肠癌:单中心经验的围手术期和中期结果。
J Surg Oncol. 2020 Dec;122(7):1453-1461. doi: 10.1002/jso.26152. Epub 2020 Aug 10.
5
Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study.结直肠癌患者以及同时性和异时性结直肠转移患者的发病情况和处理:一项基于人群的研究。
BJS Open. 2020 Aug;4(4):685-692. doi: 10.1002/bjs5.50299. Epub 2020 Jun 16.
6
Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial.同步与延迟切除对初始可切除结直肠癌肝转移的影响:一项前瞻性、开放标签、随机、对照临床试验。
Ann Surg. 2021 Jan 1;273(1):49-56. doi: 10.1097/SLA.0000000000003848.
7
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者(TRIBE2):一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
8
Achieving high quality standards in laparoscopic colon resection for cancer: A Delphi consensus-based position paper.实现腹腔镜结肠癌切除术的高质量标准:基于德尔菲共识的立场文件。
Eur J Surg Oncol. 2018 Apr;44(4):469-483. doi: 10.1016/j.ejso.2018.01.091.
9
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.FOLFOXIRI 联合贝伐珠单抗作为初始不可切除转移性结直肠癌患者的转化治疗:系统评价和汇总分析。
JAMA Oncol. 2017 Jul 13;3(7):e170278. doi: 10.1001/jamaoncol.2017.0278.
10
Totally laparoscopic strategies for the management of colorectal cancer with synchronous liver metastasis.完全腹腔镜策略在结直肠癌合并同步肝转移中的应用。
Surg Endosc. 2012 Sep;26(9):2571-8. doi: 10.1007/s00464-012-2235-2. Epub 2012 Mar 22.